Sign up for the QMED & MD+DI Daily newsletter.
Chris Newmarker
September 9, 2016
1 Min Read
Nevro (Menlo Park, CA) more than doubled its workforce to 308 in 2015 amid FDA approval of its novel Senza spinal cord stimulation technology for treating chronic leg and back pain, according to EP Vantage. By December 2015, the company had also secured reimbursement for the device.
Continue >>
[Image courtesy of Nevro]
About the Author(s)
You May Also Like